Nature Reviews Drug Discovery contents March 2012 Volume 11 Number 3 pp 169-250

Advertisement
Counting Your Cells is Not Enough! Successful cell culture requires monitoring cells from start to finish. Roche's Cedex HiRes digital imaging and label-free electrical current CASY exclusion systems are proven for automated multi-parameter quality control. http://www.roche-applied-science.com/sis/innovatis For life science research only. Not for use in diagnostic procedures.
TABLE OF CONTENTS
March 2012 Volume 11 Number 3
Impact Factor 28.712 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month Article series: Biomarkers  Featured article: Diagnosing the decline in pharmaceutical R&D efficiency Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Don't Miss Out! Are you holding the key to a research breakthrough? $3 Million in funding now available in the following areas: -Development of therapeutics that target specific B cell lineages involved in MS pathology -Identification of surrogate or endogenous ligands for Orphan G Protein-Coupled Receptors(GPCRs) in the CNS Proposals due by May 1, 2012. www.fastforward.org
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Cell Symposia on Genetics and Chemistry Sharing a Language of Discovery May 23 - 25, 2012 Boston Marriott Cambridge, Cambridge, USA Keynote Speakers: Gary Gilliland, Merck & Co., USA Eric Green, National Human Genome Research Institutes, USA Submit your abstract before March 2, 2012 for consideration in our poster program and register before March 30, 2012 to save $100!
Advertisement
JOHNS HOPKINS UNIVERSITY - MS in Bioscience Regulatory Affairs Attend an online info session for the MS in Bioscience Regulatory Affairs on March 13th. Learn how you can earn your degree ONLINE, the admission requirements, course structure, and how online education works. Learn more and RSVP online, biotechnology.jhu.edu.
In this issue p169 | doi:10.1038/nrd3696 Full Text
Comment: Alimuddin Zumla, Richard Hafner, Christian Lienhardt, Michael Hoelscher & Andrew Nunn p171 | doi:10.1038/nrd3694 Abstract | Full Text | PDF Advancing the development of tuberculosis therapy
NEWS AND ANALYSIS		Top
Protein–protein interaction inhibitors get into the groove Asher Mullard p173 | doi:10.1038/nrd3680 Drug developers are getting closer to tapping an unmined gold reserve of protein–protein interaction targets. PDF
Reverse vaccinology on the cusp Dan Jones p175 | doi:10.1038/nrd3679 An upcoming decision for Novartis's Bexsero — the first vaccine against meningococcus B — could substantiate reverse vaccinology. PDF
NEWS IN BRIEF FDA approves landmark drugs | A drug for drug-induced liver injury? | Stem cells see first light | Safety biomarker gets thumbs up p177 | doi:10.1038/nrd3697 PDF
BIOBUSINESS BRIEFS Trial watch: Integrin antagonist shows promise in MS Sarah Crunkhorn p178 | doi:10.1038/nrd3676 PDF
BIOBUSINESS BRIEFS Market watch: Industry perspectives on personalized medicine Rachael Zuckerman & Christopher-Paul Milne p178 | doi:10.1038/nrd3677 PDF
PATENT WATCH Merck loses information disclosure dispute | Generic drugs allowed on market for non-patented indications | Spleen tyrosine kinase inhibitors Charlotte Harrison p180 | doi:10.1038/nrd3695 PDF
AN AUDIENCE WITH Guido Rasi p182 | doi:10.1038/nrd3684 Guido Rasi, the recently appointed head of the European Medicines Agency, discusses his goals for the regulatory agency. PDF
FROM THE ANALYST'S COUCH Maximizing the value of diagnostics in Alzheimer's disease drug development Eric M. Snyder, Jake Olin & Frank S. David p183 | doi:10.1038/nrd3535 This article examines strategic issues faced by pharmaceutical companies relating to the development of biomarkers and diagnostics for Alzheimer's disease. PDF
FRESH FROM THE PIPELINE Tafamidis Gerard Said, Seden Grippon & Peter Kirkpatrick p185 | doi:10.1038/nrd3675 First-in-class drug that inhibits protein misfolding approved in Europe for the treatment of familial amyloid polyneuropathy. PDF
RESEARCH HIGHLIGHTS Top Viral disease: Steps towards an HCV vaccine p187 | doi:10.1038/nrd3687 PDF Metabolomics: Gaining insight into pain p188 | doi:10.1038/nrd3685 PDF Neurodegenerative disease: Harnessing virus-mediated mitochondrial protection to combat neurodegeneration p188 | doi:10.1038/nrd3688 PDF Metabolic disease: Exercise hormone fights metabolic disease p189 | doi:10.1038/nrd3686 PDF Anticancer drugs: Targeting menin p190 | doi:10.1038/nrd3689 PDF IN BRIEF Analgesia: Erasing the traces of pain | Genetic disorders: A way to prevent heat-induced sudden death? | Parasite infection: Understanding drug mechanisms of action | Anticancer drugs: Angiogenesis drug does not improve chemotherapy PDF Drug Discovery JOBS of the week Drug Safety Associate / Senior Drug Safety Associate Genentech Post-Doctoral (WW) - Target Identification and Drug Discovery - Immunobiology and Cancer Research Program (W Wang) Oklahoma Medical Research Foundation (OMRF) 10 PhD and 2 Postdoc positions in Marie Curie initial training network SPHINGONET Sr Research Assoc, Biochemical & Cellular Pharmacolgy Genentech Medical Director - Early Development - Oncology 1954 Merck Serono SA More Science jobs from Drug Discovery EVENT Drug Resistance and Persistence in Tuberculosis (E1) 13.-18.05.12 Uganda More science events from
PERSPECTIVES		Top
OPINION Diagnosing the decline in pharmaceutical R&D efficiency Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington p191 | doi:10.1038/nrd3681 The number of new drugs approved per billion US dollars spent on research and development (R&D) has fallen around 80-fold in inflation-adjusted terms since 1950, despite advances in many of the scientific and technological inputs into the R&D process. Given the apparent lack of impact of proposed solutions to declining R&D efficiency so far, Scannell and colleagues ask whether the underlying problems have been correctly diagnosed and discuss factors that they consider to be the primary causes. Abstract | Full Text | PDF | Supplementary information
Article series: Biomarkers Cancer biomarkers: selecting the right drug for the right patient Gary J. Kelloff & Caroline C. Sigman p201 | doi:10.1038/nrd3651 This Perspective highlights the sources and functions as well as the evaluation of biomarkers that are useful in cancer, with a focus on those biomarkers that are most relevant for identifying patients who are likely to respond to a given therapy, and those biomarkers that are most effective for measuring patient response to therapy. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
The secret ally: immunostimulation by anticancer drugs Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel & Guido Kroemer p215 | doi:10.1038/nrd3626 A crucial role of the immune system in cancer progression and response to therapy has recently emerged. Here, Galluzzi and colleagues discuss the immune parameters that may predict the therapeutic response of patients to chemotherapeutics, and review the mechanisms by which current antineoplastic agents activate the immune system against cancer. Abstract | Full Text | PDF
Inflammatory bone loss: pathogenesis and therapeutic intervention Kurt Redlich & Josef S. Smolen p234 | doi:10.1038/nrd3669 Bone continuously undergoes building and degradation — a process known as bone remodelling. This tightly controlled process can be dysregulated by chronic inflammation, and bone loss is commonly associated with inflammatory diseases. Here, Redlich and Smolen discuss the molecular mechanisms mediating the inflammatory loss of bone and present strategies and agents for therapeutic intervention. Abstract | Full Text | PDF
Erratum: Interfacial inhibitors: targeting macromolecular complexes Yves Pommier & Christophe Marchand p250 | doi:10.1038/nrd3665 Full Text | PDF
Corrigendum: 2011 in reflection Asher Mullard p250 | doi:10.1038/nrd3678 Full Text | PDF
Advertisement
Get your free copy of Key Advances in Medicine Key Advances in Medicine is written by international experts who identify the groundbreaking research papers published in their specialty last year. It?s a perfect resource for busy medical students, physicians, and clinical researchers who want to catch up with the medical literature from 2011. Download the free PDF today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.